Abbott Laboratories (ABT) stock has performed well against competitors even amid market losses, giving those who invested five years ago a 46% gain. The company's Q1 2024 earnings call confirmed these strong performances. However, the stock fell following a Q2 guidance that outweighed earnings beat. The company has established itself as a Dividend Aristocrat, maintaining investor interest while outperforming medical industry peers.
Financial performance took a dip in anticipation of a new diabetes drug, though the company's first-quarter 2024 results beat expectations, raising the midpoint of its full-year guidance range. Insider sales and questions about CEO compensation have slightly marred the company's reputation. Other
significant developments include an attention to organic growth, engagement in the billion-dollar weight loss market, and the potential launch of a game-changing new device in the U.S. Despite a decline in recent weeks, analysts posit strong future possible growth, especially with the expected rise in Continuous Glucose Monitor (CGM) tailwinds in 2024.
Abbott Laboratories ABT News Analytics from Wed, 11 Oct 2023 07:00:00 GMT to Fri, 24 May 2024 21:50:06 GMT -
Rating 5
- Innovation 5
- Information 9
- Rumor -1
